DCP Capital

About The Fund

DCP Capital is a leading international private equity firm with a focus on the Asian market, particularly in China. The firm specializes in providing seed investments and operates as a venture capital entity, leveraging extensive experience and local knowledge to identify and nurture promising enterprises. They are recognized for a disciplined approach to investing, emphasizing value creation and the establishment of lasting relationships. Over the past three decades, DCP Capital's team has led a series of successful and innovative investments, which has culminated in a robust investment track record, spanning multiple economic cycles. DCP Capital's investment ethos is characterized by a value-oriented approach. As long-term investors, they prioritize sustainable growth over short-term market trends, favoring industries and companies with high potential for long-term growth. This includes industry leaders with exceptional management teams and robust organizational culture. With an ingrained long-term orientation, the firm's investment strategy is underpinned by a commitment to enhancing operational capacity and efficiency within their portfolio companies. DCP Capital draws from its history of fostering some of Asia's most respected and well-managed companies, applying this expertise to the benefit of its current portfolio. Their operational focus is complemented by a partnership and cooperation-centric mindset. Adhering to a people-oriented investment philosophy, DCP Capital aims to establish mutually beneficial partnerships with superior management teams and entrepreneurs in Asia. As a region-based partnership, their decision-making process is streamlined, incorporating a deep understanding of local business culture, which positions them as ideal partners for management teams in the region. DCP Capital's most recent investment activities highlight a strategic approach to selecting investments that reinforce their thesis, as exemplified by their exclusive investment in Jamieson Wellness—Canada's leading consumer health brand—and their strategic investment in American-Sino Healthcare, a premium private healthcare service provider. Additionally, their recent agreement to sell a majority stake in Orgain to Nestlé Health Science aligns with their value creation and long-term investment strategy.